Not logged in Share Save
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma Goyal, L.; DiToro, D.; Facchinetti, F.; Martin, E. E.; Peng, P.; Baiev, I.; Iyer, R.; Maurer, J.; Reyes, S.; Zhang, K.; Majeed, U.; Berchuck, J. E.; Chen, C. T.; Walmsley, C.; Pinto, C.; Vasseur, D.; Gordan, J. D.; Mody, K.; Borad, M.; Karasic, T.; Damjanov, N.; Danysh, B. P.; Wehrenberg-Klee, E.; Kambadakone, A. R.; Saha, S. K.; Hoffman, I. D.; Nelson, K. J.; Iyer, S.; Qiang, X.; Sun, C.; Wang, H.; Li, L.; Javle, M.; Lin, B.; Harris, W.; Zhu, A. X.; Cleary, J. M.; Flaherty, K. T.; Harris, T.; Shroff, R. T.; Leshchiner, I.; Parida, L.; Kelley, R. K.; Fan, J.; Stone, J. R.; Uboha, N. V.; Hirai, H.; Sootome, H.; Wu, F.; Bensen, D. C.; Hollebecque, A.; Friboulet, L.; Lennerz, J. K.; Getz, G.; Juric, D. Share Save
Share Save
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study Yau, Thomas; Kaseb, Ahmed; Cheng, Ann-Lii; Qin, Shukui; Zhu, Andrew X.; Chan, Stephen L.; Melkadze, Tamar; Sukeepaisarnjaroen, Wattana; Breder, Valery; Verset, Gontran; Gane, Edward; Borbath, Ivan; Rangel, Jose David Gomez; Ryoo, Baek-Yeol; Makharadze, Tamta; Merle, Philippe; Benzaghou, Fawzi; Milwee, Steven; Wang, Zhong; Curran, Dominic; Kelley, Robin Kate; Rimassa, Lorenza Share Save
Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study Finn, Richard S.; Kudo, Masatoshi; Barnes, Gisoo; Meyer, Tim; Boisserie, Frederic; Abdrashitov, Ramil; Chen, Yaxi; Li, Songzi; Zhu, Andrew X.; Qin, Shukui; Vogel, Arndt Share Save
First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors Ku, G.; Shen, L.; Klempner, S. J.; Pan, H.; Kratz, J.; Liang, X.; Deng, Y.; Kim, S.; Wang, Z.; Feller, L.; Powderly, J.; Dayyani, F.; Schneider, R. E.; Girda, E.; Berlin, J. D.; Spencer, K.; Nguyen, M. T.; Wang, V.; Xu, C.; Zhu, A. Share Save
Share Save
Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age ≥65 years subgroup Vogel, A.; Kudo, M.; Qin, S.; Chen, Y.; Li, S.; Boisserie, F.; Abdrashitov, R.; Finn, R.; Meyer, T.; Zhu, A. Share Save
Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma Spencer, Kristen; Pappas, Leontios; Baiev, Islam; Maurer, Jordan; Bocobo, Andrea Grace; Zhang, Karen; Jain, Apurva; De Armas, Anaemy Danner; Reyes, Stephanie; Le, Tri Minh; Rahma, Osama E.; Stanton, Jennifer; DeLeon, Thomas T.; Roth, Marc; Peters, Mary Linton B.; Zhu, Andrew X.; Lennerz, Jochen K.; Iafrate, A. John; Boyhen, Kylie; VanCott, Christine; Roberts, Lewis R.; Lindsey, Stacie; Horick, Nora; Goff, Laura Williams; Mody, Kabir; Borad, Mitesh J.; Shroff, Rachna T.; Kelley, Robin Kate; Javle, Milind M.; Goyal, Lipika Share Save
Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study Kudo, Masatoshi; Finn, Richard S.; Cheng, Ann-Lii; Zhu, Andrew X.; Ducreux, Michel; Galle, Peter R.; Sakamoto, Naoya; Kato, Naoya; Nakano, Michitaka; Jia, Jing; Vogel, Arndt Share Save
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer Berchuck, J. E.; Facchinetti, F.; DiToro, D. F.; Baiev, I; Majeed, U.; Reyes, S.; Chen, C.; Zhang, K.; Sharman, R.; Uson, P. L. S., Jr.; Maurer, J.; Shroff, R. T.; Pritchard, C. C.; Wu, M-J; Catenacci, D. V. T.; Javle, M.; Friboulet, L.; Hollebecque, A.; Bardeesy, N.; Zhu, A. X.; Lennerz, J. K.; Tan, B.; Borad, M.; Parikh, A. R.; Kiedrowski, L. A.; Kelley, R. K.; Mody, K.; Juric, D.; Goyal, L. Share Save
IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma-An Exploratory Analysis of the Phase III Study Kudo, Masatoshi; Finn, Richard S. S.; Galle, Peter R. R.; Zhu, Andrew X. X.; Ducreux, Michel; Cheng, Ann-Lii; Ikeda, Masafumi; Tsuchiya, Kaoru; Aoki, Ken-ichi; Jia, Jing; Lencioni, Riccardo Share Save
Share Save
Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus Bevacizumab Hsu, Chiun; Ducreux, Michel; Zhu, Andrew X.; Qin, Shukui; Ikeda, Masafumi; Kim, Tae-You; Galle, Peter R.; Finn, Richard S.; Chen, Ethan; Ma, Ning; Hu, Youyou; Li, Lindong; Cheng, Ann-Lii Share Save
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma Zhu, Andrew X.; Abbas, Alexander R.; de Galarreta, Marina Ruiz; Guan, Yinghui; Lu, Shan; Koeppen, Hartmut; Zhang, Wenjun; Hsu, Chih-Hung; He, Aiwu Ruth; Ryoo, Baek-Yeol; Yau, Thomas; Kaseb, Ahmed O.; Burgoyne, Adam M.; Dayyani, Farshid; Spahn, Jessica; Verret, Wendy; Finn, Richard S.; Toh, Han Chong; Lujambio, Amaia; Wang, Yulei Share Save
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib Kudo, Masatoshi; Finn, Richard S.; Edeline, Julien; Cattan, Stephane; Ogasawara, Sadahisa; Palmer, Daniel H.; Verslype, Chris; Zagonel, Vittorina; Fartoux, Laetitia; Vogel, Arndt; Sarker, Debashis; Verset, Gontran; Chan, Stephen L.; Knox, Jennifer; Daniele, Bruno; Yau, Thomas; Gurary, Ellen B.; Siegel, Abby B.; Wang, Anran; Cheng, Ann-Lii; Zhu, Andrew X. Share Save
IFNa Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment Hu, Bo; Yu, Mincheng; Ma, Xiaolu; Sun, Jialei; Liu, Chenglong; Wang, Chunyan; Wu, Suiyi; Fu, Peiyao; Yang, Zhen; He, Yungang; Zhu, Yuanyuan; Huang, Cheng; Yang, Xinrong; Shi, Yinghong; Qiu, Shuangjian; Sun, Huichuan; Zhu, Andrew X.; Zhou, Jian; Xu, Yang; Zhu, Di; Fan, Jia Share Save
Donor and recipient polygenic risk scores influence the risk of post-transplant diabetes Shaked, Abraham; Loza, Bao-Li; Van Loon, Elisabet; Olthoff, Kim M.; Guan, Weihua; Jacobson, Pamala A.; Zhu, Andrew; Fishman, Claire E.; Gao, Hui; Oetting, William S.; Israni, Ajay K.; Testa, Giuliano; Trotter, James; Klintmalm, Goran; Naesens, Maarten; Asrani, Sumeet K.; Keating, Brendan J. Share Save
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma Cheng, Ann-Lii; Qin, Shukui; Ikeda, Masafumi; Galle, Peter R.; Ducreux, Michel; Kim, Tae-You; Lim, Ho Yeong; Kudo, Masatoshi; Breder, Valeriy; Merle, Philippe; Kaseb, Ahmed O.; Li, Daneng; Verret, Wendy; Ma, Ning; Nicholas, Alan; Wang, Yifan; Li, Lindong; Zhu, Andrew X.; Finn, Richard S. Share Save
Share Save
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Not logged in.png){kind=icon}